New Medications

In a phase 3 trial, inebilizumab, a monoclonal antibody targeting CD19+ B cells, reduced flare rates and improved treatment-free and glucocorticoid-free remission in patients with immunoglobulin G4-related...

Two phase 3 randomized trials evaluated the efficacy of risankizumab in patients with moderately to severely active ulcerative colitis. The results show significantly higher remission rates with...

Two randomized, double-blind studies demonstrated that a new antipsychotic treatment for adult patients with schizophrenia may lead to a meaningful reduction in symptoms.

The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...

The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.

The FDA has approved empagliflozin, and empagliflozin and hydrochloride to help manage type 2 diabetes in pediatric patients.

The FDA approved the first treatment for pediatric patients who experience functional constipation

The US FDA recently approved a novel treatment for moderate to severe vasomotor symptoms that are caused by menopause.